Hypoglycemia in the Context of Post-Bariatric Clinical Follow-Up: Is There a Blind Spot in Research and Care?

Daniel Sant'Anna da Silva, Karynne Grutter Lopes, Luiz Guilherme Kraemer-Aguiar

Journal: Clinical obesity 2026;16(4):e70090

PMID: 42309518

Abstract

Post-bariatric hypoglycemia (PBH) is classically defined as venous glucose levels < 54 mg/dL accompanied by sympathetic or neuroglycopenic symptoms, with resolution after glucose correction (Whipple's triad), occurring in a typical post-surgical context (1-3 years after surgery, 2-4 h postprandially), after exclusion of other causes. Since 2015, studies using continuous glucose monitoring (CGM) have revealed a more complex glycemic profile following metabolic bariatric surgery (MBS) characterised by CGM-detected asymptomatic and nocturnal low interstitial glucose values, frequently occurring during prolonged intermeal periods, along with increased 24-h glycemic variability. Provocative tests are limited by non-physiological stimuli or poor standardisation. Meanwhile, although diagnostic workups for alternative etiologies not related to diabetes are recommended, these conditions are exceedingly rare compared with real-world CGM-detected events. Evidence from cohorts of individuals with diabetes links CGM metrics, such as nocturnal and prolonged intermeal low glucose exposure and glycemic variability, to adverse outcomes, including cardiovascular mortality, stroke, arrhythmias, next-day cognitive slowing, retinopathy, microalbuminuria, and arterial stiffness. These findings may support the potential prognostic relevance of similar phenotypes following MBS. We argue for: (1) a critical revision of diagnostic criteria, including standardised interstitial thresholds, event definitions, and the role of symptoms; and (2) prospective CGM cohorts of post-MBS patients without diabetes adequately sized to assess clinically meaningful endpoints, such as cardiovascular, microvascular, and cognitive outcomes. CGM has uncovered a likely blind spot in PBH, particularly asymptomatic and nocturnal hypoglycemia. Recognising this spectrum and aligning definitions, diagnostics, and care may improve outcomes.

© 2026 World Obesity Federation.

Address: Postgraduate Program in Clinical and Experimental Physiopathology, Faculty of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro, Brazil.; Obesity Unit, Multiuser Clinical Research Center, Pedro Ernesto University Hospital, State University of Rio de Janeiro, Rio de Janeiro, Brazil.; Postgraduate Program in Clinical and Experimental Physiopathology, Faculty of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro, Brazil.; Obesity Unit, Multiuser Clinical Research Center, Pedro Ernesto University Hospital, State University of Rio de Janeiro, Rio de Janeiro, Brazil.; Laboratory for Clinical and Experimental Research on Vascular Biology, Biomedical Center, State University of Rio de Janeiro, Rio de Janeiro, Brazil.; Department of Physiological Sciences, Roberto Alcantara Gomes Biology Institute, State University of Rio de Janeiro, Rio de Janeiro, Brazil.; Postgraduate Program in Clinical and Experimental Physiopathology, Faculty of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro, Brazil.; Obesity Unit, Multiuser Clinical Research Center, Pedro Ernesto University Hospital, State University of Rio de Janeiro, Rio de Janeiro, Brazil.; Laboratory for Clinical and Experimental Research on Vascular Biology, Biomedical Center, State University of Rio de Janeiro, Rio de Janeiro, Brazil.; Endocrinology, Department of Internal Medicine, Faculty of Medical Sciences, State University of Rio de Janeiro, Rio de Janeiro, Brazil.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.